Supplementary Material: Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

Jaume Mora 1,*, Alicia Castañeda 1, Maria Cecilia Colombo 2, Maite Gorostegui 1, Fernando Gomez 3, Salvador Mañé 4, Vicente Santa-Maria 1, Moira Garraus 1, Napoleon Macias 3, Sara Perez-Jaume 1, Oscar Muñoz 1, Juan Pablo Muñoz 1, Ignasi Barber 2 and Mariona Suñol 5

Figure S1. Histological picture of undifferentiated NB from patient #1 at diagnosis (before immunotherapy). A flow chart summary of all patients managed with naxitamab at HSJD is shown as supplementary material.

- **201 Trial** (27 pts):
  - CR pts = 16 (59%)
  - PD pts = 7 (26%)
  - PR/SD = 4 (15%)

- **HITS Study** (44 pts)
  - CR pts = 17 (39%)
  - PD pts = 4 (9%)
  - PR/SD = 23 (52%)

2 pts MIBG⁺ and FDG-PET⁻

12 pts MIBG⁺ and FDG-PET⁻